The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| PROG | -100% | -100% | -96.53% | -100% |
| S&P | +14.5% | +93.32% | +14.09% | +116% |
Biora Therapeutics, Inc. engages in the provision of molecular and specialized diagnostic tests to clinicians. Its products include the Preparent Carrier Test, Innatal Prenatal Screen, Riscover Hereditary Cancer Test, and Resura Prenatal Test. The company was founded by Paul W. Hawran and Harry Stylli in 2010 and is headquartered in San Diego, CA.
The biotech has given investors a bumpy ride this month.
Shares of the biotech stock rose more than $1.50 per share Tuesday morning.
| Q3 2024 | YOY Change | |
|---|---|---|
| Revenue | $0.03M | 0.0% |
| Gross Profit | -$0.08M | 0.0% |
| Gross Margin | -246.88% | 0.0% |
| Market Cap | $18.45M | 0.0% |
| Market Cap / Employee | $0.32M | 0.0% |
| Employees | 58 | 0.0% |
| Net Income | -$22.22M | 0.0% |
| EBITDA | -$16.12M | 0.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2024 | YOY Change | |
|---|---|---|
| Net Cash | $3.20M | 0.0% |
| Inventory | 0 | 0.0% |
| Q3 2024 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.34M | 0.0% |
| Short Term Debt | $39.31M | 0.0% |
| Q3 2024 | YOY Change | |
|---|---|---|
| Return On Assets | -144.59% | 0.0% |
| Return On Invested Capital | 138.79% | 0.0% |
| Q3 2024 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$8.75M | 0.0% |
| Operating Free Cash Flow | -$8.73M | 0.0% |
| Metric | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | -0.27 | -0.30 | -0.20 | -0.17 | - |
| Price to Sales | 8373.69 | 59.24 | 56.96 | 20.54 | - |
| Price to Tangible Book Value | -2.53 | -2.85 | -1.89 | -1.89 | - |
| Enterprise Value to EBITDA | -4.97 | -4.42 | -5.78 | -3.40 | - |
| Total Debt | $47.43M | $46.76M | $46.96M | $39.65M | - |
PROG earnings call for the period ending June 30, 2021.
PROG earnings call for the period ending March 31, 2021.
PROG earnings call for the period ending December 31, 2020.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
